GSK_ Annual_Report_2021-22

Notes to the Consolidated Financial Statements for the year ended March 31, 2022 249 Effect in ` Lakhs Strengthening / Weakening % (Profit) or loss Equity Strengthening Weakening Strengthening Weakening As at March 31, 2022 GBP 5% 2,10.99 (2,10.99) - - USD 5% (4,02.66) 4,02.66 - - EUR 5% (11.05) 11.05 - - Other currencies 5% - - - - Effect in ` Lakhs Strengthening / Weakening % (Profit) or loss Equity Strengthening Weakening Strengthening Weakening As at March 31, 2021 GBP 5% (97.77) 97.77 - - USD 5% (4,86.44) 4,86.44 - - EUR 5% (30.86) 30.86 - - Other currencies 5% (4.66) 4.66 - - (Note: The impact is indicated on the profit/loss before tax basis) Note 51 : Capital Management (a) Risk Management The Group’s policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Management monitors the return on capital as well as the level of dividends to ordinary shareholders. The Group has adequate cash and bank balances and no interest bearing liabilities.The Group monitors its capital by a careful scrutiny of the cash and bank balances, and a regular assessment of any debt requirements. In the absence of any interest bearing debt, the maintenance of debt equity ratio etc. may not be of any relevance to the Group. No changes were made in the objectives, policies or processes for managing capital during the years ended March 31, 2022 and March 31, 2021. (b) Dividend distribution and proposed dividend ( ` in lakhs ) As at March 31, 2022 As at March 31, 2021 (i) Equity shares Final dividend for the year ended March 31, 2021 of ` 30 (March 31, 2020: ` 40) per fully paid share 508,21.81 677,62.41 (ii) Dividends not recognised at the end of the reporting period In addition to the above dividends, since year end the directors have recommended the payment of a final dividend of ` 90 per fully paid equity share (including special dividend of ` 60 per equity share)(March 31, 2021: ` 30 per fully paid equity share). The proposed dividend for the year ended March 31, 2022 is subject to the approval of shareholders in the ensuing annual general meeting. 152,473.88 508,24.63